Who are Plavix with Astrix's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Oral P2Y12 receptor blocker.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/plavix-with-astrix.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-15 · How we verify

Plavix with Astrix — Competitive Intelligence Brief

Plavix with Astrix (Plavix with Astrix) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antiplatelet agent (P2Y12 inhibitor). Area: Cardiovascular.

marketed Antiplatelet agent (P2Y12 inhibitor) P2Y12 adenosine diphosphate receptor Cardiovascular Small molecule Live · refreshed every 30 min

Target snapshot

Plavix with Astrix (Plavix with Astrix) — Seoul St. Mary's Hospital. Plavix (clopidogrel) inhibits platelet aggregation by blocking the P2Y12 adenosine diphosphate receptor, reducing thrombotic events.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Plavix with Astrix TARGET	Plavix with Astrix	Seoul St. Mary's Hospital	marketed	Antiplatelet agent (P2Y12 inhibitor)	P2Y12 adenosine diphosphate receptor
Oral P2Y12 receptor blocker	Oral P2Y12 receptor blocker	Italian Society of Invasive Cardiology	marketed	Antiplatelet agent; P2Y12 receptor antagonist; Thienopyridine or non-thienopyridine class	P2Y12 adenosine diphosphate receptor on platelet surface

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antiplatelet agent (P2Y12 inhibitor) class)

Seoul St. Mary's Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Plavix with Astrix — Competitive Intelligence Brief. https://druglandscape.com/ci/plavix-with-astrix. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab